Long-term reduction in IOP due to uneventful surgical procedures in PXG patients

Article

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years.

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years, claims a paper published in the Journal of Cataract and Refractive Surgery.

Dr Bradford J. Shingleton et al., Center for Eye Research and Education, Boston, Massachusetts, USA, performed a retrospective, comparative case series analysis on consecutive eyes with pseudoexfoliation glaucoma (PXG) that underwent uneventful combined phacoemulsification and trabeculectomy. Change in intraocular pressure (IOP), glaucoma medication requirements and logMAR corrected distance visual acuity was compared between the phaco-only group and the combined surgery group.

Mean IOP and glaucoma medication requirements significantly reduced when patients underwent combined surgery, compared to the phaco-only group. Reduction in mean postoperative IOP was more significant in eyes with a higher mean preoperative IOP. Of the eyes included in the combined-surgery group, 13.8% needed subsequent laser trabeculoplasty, glaucoma surgery or a combination of the two.

Combined surgical procedures lead to long-term reductions in IOP and glaucoma medication requirements, as well as fewer 1-day postoperative spikes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.